QRG Capital Management Inc. Has $263,000 Holdings in Halozyme Therapeutics, Inc. $HALO

QRG Capital Management Inc. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,055 shares of the biopharmaceutical company’s stock after buying an additional 644 shares during the quarter. QRG Capital Management Inc.’s holdings in Halozyme Therapeutics were worth $263,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wealth Preservation Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the first quarter valued at approximately $32,000. SVB Wealth LLC acquired a new position in shares of Halozyme Therapeutics in the first quarter valued at approximately $33,000. Bessemer Group Inc. boosted its holdings in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 207 shares during the period. Brooklyn Investment Group boosted its holdings in shares of Halozyme Therapeutics by 1,558.1% in the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 670 shares during the period. Finally, Park Place Capital Corp boosted its holdings in shares of Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 182 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at approximately $55,285,726.65. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bernadette Connaughton sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total transaction of $294,720.00. Following the transaction, the director directly owned 46,952 shares in the company, valued at approximately $3,459,423.36. This represents a 7.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 108,227 shares of company stock valued at $7,779,595 over the last ninety days. 2.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on HALO shares. Morgan Stanley increased their target price on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an “overweight” rating in a report on Monday, August 18th. Zacks Research cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Benchmark increased their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. JPMorgan Chase & Co. increased their target price on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Finally, The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They set a “neutral” rating and a $55.00 target price for the company. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $70.44.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $64.10 on Friday. The firm has a market capitalization of $7.50 billion, a PE ratio of 14.67, a PEG ratio of 0.34 and a beta of 1.16. The company’s 50-day moving average is $71.08 and its 200-day moving average is $61.99. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $79.50. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company’s revenue was up 40.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.